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 INTRODUCTION 
              Photochemotherapy is one of the oldest known light dependant 
therapies in medicine. 
              Psoralen photochemotherapy is a combination of psoralen and 
long wave ultraviolet radiation that brings therapeutically beneficial 
results not produced by either drug or irradiation alone. Initially plant 
sources of psoralen were used  and patients were exposed to sunlight for a 
specified period. This method has been modified over several years and 
synthetic drug preparations and also artificial sources of light have been 
introduced. This has made possible the accurate measurement of the UV 
dose given and also helped in better treatment results. 
                Initially photochemotherapy was used in the treatment of 
vitiligo. Gradually its uses have expanded and is currently being used in 
the treatment of several common and uncommon skin diseases. 
                 But PUVA has also got various side effects which are both 
acute and long-term effects. Higher cumulative dosage is known to cause 
various skin cancers. Hence appropriate administration and regular 
monitoring is very essential. Also PUVA therapy requires good patient 
compliance and regular treatment schedules. 
             Thus if the correct category of patients are selected and PUVA 
administered as per various guidelines mentioned it can indeed be an 
extremely beneficial therapy for various diseases. 
             The study here includes the efficacy of PUVA in various 
common skin conditions encountered in the Dermatology department. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 REVIEW OF LITERATURE 
HISTORY 
The concept of photochemotherapy or the therapeutic use of 
chemical in conjunction with radiation existed more than 3000 years ago. 
Its first use was documented in ancient Hindu scriptures1. Psoralens are 
derived from plants such as Ammimajus found in Egypt and Indian plant 
such as Babachee which is also called Psoralia corylifolia. Psoralens have 
been found in more than 30 plants such as lime, lemon, bergomet, 
parsley, celery, fig and cloves. ElMofty at the University of Cairo first 
used a purified psoralen obtained from the plant Ammi majus for the 
treatment of vitiligo. Methoxalen(8-methoxypsoralen,8-MOP) was 
introduced to the United States in 1951. Trioxalen 4, 5, 8 Trimethyl 
psoralen a synthetic compound was introduced in 1964. 
Finally psoralen chemotherapy as it is commonly applied today 
was introduced in 1974 when investigations at the Massachusetts general 
hospital reported complete clearing in 21 patients treated with systemic 8-
MOP followed by newly developed high intensity radiation provided by 
Sylvania2 .The acronym PUVA was introduced by the same group. Bath 
PUVA originated in Scandinavia. 
 
  
PSORALENS AND PHARMACOKINETICS 
Psoralen and many of its derivatives are naturally occurring tricylic 
furocoumarins. The derivatives most widely used are: 
1. 8-Methoxypsoralen (8-MOP, methoxsalen, xanthotoxin) 
It is one of the most commonly used drugs in our country. It is 
lipophilic and poorly soluble in water. 
Pharmacokinetics: 
It is absorbed from gastrointestinal tract when taken orally. The 
factors affecting absorption include: 
1. Physical formulation of the compound- Liquid preparations are better 
absorbed, peak levels occurring one hour earlier when compared to 
crystalline preparations3. More important the total dose of UVA radiant 
energy was reduced by 40%.These liquid preparations have been 
approved by the FDA and are available in USA from March 1987. 
2. Diet- It did not very much affect the bioavailability of 8-MOP but a 
high fat diet retarded the absorption of 8-MOP3. Thus psoralen is best 
given under fasting condition even though nausea may be a problem. 
3. Inter and intra individual  variation- This may occur due to varied 
intestinal absorption, first pass metabolism and elimination of the drug. 
 
 Metabolism: 
Psoralens are metabolized in the liver by CYT P450 dependant 
microsomal enzymes. 8-MOP has a serum half life of 1hour and are 
degraded within 12hours and excreted mainly in the urine. Within the 
same individual, serum levels of 8-MOP correspond with skin reactivity, 
the peak of skin photo toxicity coinciding with peak serum levels4. 
Individuals with a high clearance and low maximum serum concentration 
usually show reduced sensitivity to PUVA5. These patients are those not 
responding to the usual dose, they may respond to higher dose of psoralen 
or to the administration of the drug by other routes such as bath water 
delivery. Psoralen appears to be distributed to all cell tissues after oral 
administration and there is no risk of accumulation in any organ in 
patients with normal liver and kidney function. 
Dosage-0.6 to 0.8mg/kg body weight 
2. 5-Methoxy psoralen (Bergapten). 
This differs structurally from 8-MOP in the position of the 
methoxy group on the coumarin ring. It is less water soluble and has an 
intestinal rate of absorption of only 25% that of 8-MOP.It is rapidly 
metabolized with a serum half life of 1 hour. The advantages are lower 
incidence of short term side effects such as nausea, vomiting, pruritus and 
phototoxicicity6. On the other hand it causes higher degrees of 
pigmentation and requires greater cumulative UVA dosage. A new 
 micronised tablet has been developed which has increased bioavailability, 
increased efficacy and decreased adverse effects. 
Dosage:-1.2-1.5mg/kg body weight 
3.  4,5,8 Trimethylpsoralen(TMP, Trioxsalen) 
It is a synthetic compound which is less phototoxic after oral 
administration. It has minimal gastrointestinal absorption. A peak serum 
concentration is reached 2 hours after ingestion.  The plasma level after 
oral therapy is usually not sufficient enough for Psoriasis treatment but 
effective for vitiligo therapy7. 
TMP is efficiently and predominantly used via Bath water delivery8 
Dosage- 0.3 to 0.8 mg/kg body wt. 
In USA, Food and Drug administration approved the use of psoralen in 
PUVA therapy in May 1982.3 
4.Newer compounds:- 
They include Angelicins (angular furocoumarins) and substituted 
psoralens (Pyridopsoralen).These compounds are reported to produce less 
erythema and have good antipsoriatic activity.9,10. Hence it is useful in the 
treatment of psoriasis. 
 
 
 
 Psoralen photochemotherapy and mechanism of action: 
Ground state psoralen molecules are activated to the excited singlet 
state by absorption of photons in the UVA wave band. The peak of 
absorption spectrum is around 320-330nm. 
Mode of action of psoralens occurs at the following levels:11 
1. Cell nuclei (DNA and chromatin)-Type 1 reaction 
2. Cell membrane of epidermal, dermal and endothelial cells - Type 2 
reaction 
3. Cytoplasmic constituents (enzymes, RNA, lysosomes, etc) - Type 2 
reaction. 
Type 1 reaction- 
 It is an anoxic reaction not requiring oxygen and the site of 
cellular damage is primarily in the DNA of cell nuclei. In the first step of 
this photochemical reaction a monofunctional adduct with thymine or 
cytosine is formed. Some psoralens, including 8-MOP, TMP and 5-MOP 
can absorb a second photon and this reaction can lead to the formation of 
a bifunctional adduct with 5, 6 double bond of the pyrimidine base of 
opposite strand, thus producing an interstrand cross-link of double helix. 
This intercalation of psoralen with epidermal DNA produces a 
suppression of both DNA synthesis and cell division. It can revert 
pathologically altered pattern of keratinocytes differentiation markers and 
reduce the number of proliferating epidermal cells.  
  This type 1 reaction occurs immediately and subsequently cell 
proliferation is also inhibited in patients with psoriasis who receive 
PUVA treatment. 
Type 2 reaction- 
In this reactive oxygen species induce oxidation of cellular 
lipoprotein membrane lipids, destruction of membrane bound 
cytochromes P-450, and the activation of the cyclooxygenase pathway, 
which results in an increase of secondary oxidation products that 
contribute to increased synthesis of eicosanoids. The reactive oxygen 
species can directly damage DNA by generating DNA strand breaks. 
PUVA down regulates certain lymphocytes and antigen presenting 
cell functions, influences adhesion molecule expression, diminishes 
Langerhan cell numbers within epidermis. PUVA also affect specific 
cells such as lymphocytes and polymorphonuclear leucocytes. A decrease 
in the percentage of T lymphocytes following PUVA treatment has been 
reported. 12 Infiltrating lymphocytes are strongly suppressed by PUVA 
and PUVA can induce apoptosis in lymphocytes. 
                Psoralens also stimulate melanogenesis. This involves the 
photoconjugation of psoralens in melanocytes, mitosis and subsequent 
proliferation of melanocytes, an increased formation and melanisation of 
melanosomes, increased transfer of melanosomes to keratinocytes and 
increased synthesis of tyrosine mediated by stimulation of C-AMP 
 activity. It may also correct the structural abnormalities in the 
melanocytes in vitiligo skin. 
 
Ultraviolet Radiation spectrum and PUVA 
Sunlight comprises of a spectrum of electromagnetic waves as 
follows 
1.  Gamma and Cosmic rays - Range <100nm 
2.  Ultraviolet rays   - Range 100-400nm 
3.  Visible spectrum            - Range 400-700nm 
4.  Infrared rays   - Range >700nm. 
 
The ultraviolet range includes 
UVA:   320-400 nm 
UVB:   280-320nm 
UVC:   100-280nm. 
 
The PUVA action spectrum is defined as the effectiveness of 
clearing psoralen- sensitized psoriasis as a function of wavelength. 
Currently broad band high intensity UVA sources ranging from320-
400nm with a peak emission at 352nm are typically used in PUVA. 13 
 
 
 The LIGHT SOURCES: 
The commonly used lamps are 
1. Flourescent lamps 
2. Metal halide lamps 
Fluorescent lamps are low pressure mercury arc discharge sources 
encased in phosphor coated glass. The mercury arc discharge source 
releases radiation that is absorbed by phosphor, which undergoes 
excitation, re-emitting energy at longer wavelength via fluorescence. 14 
Metal halide lamps are medium to high pressure mercury arcs 
housed within quartz. The type of filter used with each lamp determines 
its emission spectrum. 
PHOTOSENSITIVITY EFFECTS OF PUVA: 
1. It produces an inflammatory response that manifests as delayed 
phototoxic erythema. 14,15.  It does not appear before 24 hours to 36 
hours and it peaks at 72-96 hours. 
2. Pigmentation is the second important effect .It maximizes 7 days 
after a PUVA exposure and may last from several weeks to 
months. 
3. Intense pruritus and sometimes peculiar stinging sensation in the 
affected area may occur as a consequence of damage to superficial 
nerve endings. 
 
 TREATMENT PROCEDURES 
Preliminary tests to be done before starting PUVA are 
1. Complete Hemogram 
2. Blood urea, serum creatinine, blood sugar 
3. Liver function tests 
4. Ophthalmological evaluation to rule out cataract 
The contraindications to PUVA16 which are to be excluded before starting 
treatment are 
1.Absolute contraindications: 
a. Xeroderma pigmentosum, Blooms syndrome and congenital       
photosensitivity disorders   
b. Lupus erythematosus 
c. Pemphigus and Pemphigoid17 
d. History of idiosyncratic reactions 
2. Relative contraindications: 
a. Concurrent photosensitivity medications 
b. Prior exposure to ionizing radiation or arsenic18 
c. History of skin cancer/chronic actinic damage18 
d. Personal or family history of melanoma19 
e. Pregnancy, lactation20 
f. Age <18 years 
 
 g. Significant renal, hepatic or cardiac dysfunction13 
h. Cataract21 
The initial UVA doses are established either by skin types or by 
minimal phototoxicity dose testing (MPD). 22 
Skin Phototypes  Recommended Dose 
1 Always burn never tan 0.5 j/cm2 
2 Always burn sometimes tan 1.0 j/cm2 
3 Sometimes burn, always tan 1.5 j/cm2 
4 Never burn sometimes tan 2.0 j/cm2 
5 Moderately pigmented 2.5 j/cm2 
6 Deeply pigmented 3.0 j/cm2 
 
Types 1 to 4 are determined by history  
Types 4 to 6 by physical examination 
 
Determination of  MINIMAL PHOTOTOXICTY DOSE (MPD): 23,24. 
One hour after administration of oral psoralen, a template is placed 
on the patient’s buttocks, as it is the area of greatest UV sensitivity. The 
template consists of 6 to 8 areas of at least 1 cm2, which can be exposed 
 to increasing doses of UVA. Visual assessment of the erythema response 
is preformed at 72hours using a grading scale. The MPD is the lowest 
dose that produces pink erythema with distinct borders 72hours after 
exposure. A fraction of this dose e.g. 50-80% is frequently used as a 
starting dose in PUVA therapy. 
Among these two methods, the best way to begin PUVA therapy is 
to determine patients MPD. 25 It ensures that the patients will receive a 
starting dose that is neither too high resulting in phototoxicity nor too low 
causing ineffective therapy. Another potential advantage if the MPD is 
that, fewer treatments are needed and thus the carcinogenic potential may 
be lower 26 
To increase or maximize the efficacy of PUVA treatment and to 
reduce the treatment duration and cumulative dose, a weekly minimal 
phototoxic dose was introduced. 27 There is a substantial advantage from 
this logical approach. 
 
INDICATIONS FOR PUVA THERAPY 28,29. 
FDA approved 
1. Psoriasis 
a. Chronic plaque type of psoriasis involving greater than 
20% body surface area 
b. Erythrodermic psoriasis 
 c. Generalized pustular psoriasis 
d. Palmoplantar psoriasis 
2. Vitiligo30 
Other uses include 
3. Mycosis fungoides 
4. Lymphomatoid papulosis 
5. Pityriasis lichenoides 
6. Langerhan cell histiocytosis 
7. Atopic dermatitis13 
8. Seborrhoeic dermatitis 
9. Chronic hand eczema 
10. Pityriasis rubra pilaris 
11. Generalised lichen planus31 
12. Lichen nitidus 
13. Alopecia areata 
14. Cutaneous graft versus host disease32 
15. Morphoea 
16. Urticaria pigmentosa 
17. Aquagenic pruritus 
18. Chronic urticaria 
19. Actinic prurigo33 
20. Nodular prurigo29 
 21. Pityriasis alba34 
22. Generalised granuloma annulare 
23. Grovers disease 
24. Pigmented purpuric dermatosis 
25. Scleredema adultorum35 
PUVA for prevention of disease- 
In certain conditions, small doses of PUVA are given for a 
specified period and this will lead to desensitization. They include: 
1. Polymorphic light eruption36 
2. Hydroa vacciniforme 
3. Solar urticaria 
4. Erythropoietic protoporphria 
5. Chronic actinic dermatitis 
 
ADVERSE EFFECTS  
Short term: 
A. Phototoxic reactions: 
1. Erythema and frank sunburn- most common side effects(30%)37 
2. Pruritus (25%)38 
3. Sever cutaneous pain- It is a rare symptom and starts at 4-8 weeks 
after onset of PUVA therapy and sometimes after treatment has 
been stopped. Attacks may last from 15mins to several hours, and 
 can be provoked by scratching or pressure. The buttocks and limbs 
are particularly affected, especially at night. The pain is not 
associated with itching. It settles over a few weeks. 39,40 
4. Blistering on hands and feet. 
5. Photoonycholysis and pigmentation of nails41 
6. Phytophotodermatitis 
B. Due to psoralen: 
1. Nausea and vomiting (12%) 
2. Headache 
3. Dizziness 
4. Bronchoconstriction 
5. Hepatotoxicity42 
6. Drug fever 
7. Exanthems 
Other side effects: 
1. Hypertrichosis of the face especially in females43 
2. Mild facial dermatitis resembling seborrhoeic dermatitis and 
involving the glabella, cheeks and nasolabial folds 
3. Acneform eruptions 
4. Pigmentation- diffuse or poikiloderma like or in a naevus spilus 
like pattern, producing gross freckling (PUVA Lentigenes). 44 
5. Induction of bullous pemphigoid.45 
 6. Lichenoid eruptions and histology of unaffected skin may show 
colloid or amyloid bodies in dermo epidermal junction. 46 
7. Rarely abnormal liver function tests may occur and psoralens are 
known to induce liver microsomal enzymes. 47 
       PUVA erythema is the most commonest phototoxic reaction.42 
Cool bath, aspirin, antipruritics and topical steroids may be given. 
Pruritus may be relieved by capsaicin. For very severe pruritus, phenytoin 
150mg BD may relieve the symptoms. 
Gastrointestinal side effects like nausea and vomiting can be 
overcome by either 
1. Ingesting 8-MOP with food 
2. Reducing the dose or 
3. Using 5-MOP instead of 8-MOP which is less nauseating. 
      The concurrent administration of other photoactive drugs 
increase the chances of unpleasant erythematous reactions.48 
Worsening or new eruptive psoriasis, resulting from a Koebner 
phenomenon, occurs in about 2% of patients. 
       Lupus erythematosus like syndrome can rarely occur and ANA 
titer and circulating immune complexes may be raised. 49 
 
 
 
 Long Term adverse effects 
1. Chronic actinic damage 
2. Carcinogenesis 
3. Immunological 
4. Ophthalmological  
 
1. Chronic actinic damage-50 
Premature photo ageing may be a consequence of high cumulative 
UVA exposure associated with long term PUVA therapy. It results due to 
damage to collagen and elastin. PUVA lentigenes exhibit irregular 
borders and uneven pigmentation. The melanocytes are abnormal within 
these lentigenes, with large melanosomes and lipid accumulations.51 
These changes may be partially reversible. Actinic kertoses may occur. A 
case of superficial actinic porokeratosis has been reported.52 
2. Carcinogenesis- 
 This is due to reactivity of psoralens with DNA forming mono and 
bifunctional adducts. PUVA induced downregulation of immune 
responses may play an additional role. 
Long term use of PUVA has been clearly associated with increased 
risk of developing cutaneous squamous cell carcinoma and basal cell 
carcinoma. However more recent advances indicate an increased risk of 
squamous cell carcinoma.53 Stern found a specific increase of cutaneous 
 carcinoma in the genital skin of male patients.54 Shielding of genitalia 
during PUVA reduces the risk. 
There is also an increased risk (8.4 fold) of malignant melanoma in 
patients who receive high dose PUVA. So it is best avoided in those 
predisposed to malignant melanoma (those with numerous melanocytic 
naevi or atypical moles and a family history of melanoma). 55 
Most studies thus advice to keep cumulative dose of PUVA low 
and use it in a rotational therapy or sequential therapy with other drugs. 
3.Immunological effects- 
Reduction in circulating T-lymphocytes numbers and function is 
documented. 56 A reduction in circulating helper –inducer T cells may 
also occur with long term PUVA therapy. Inhibition of lymphocyte DNA 
synthesis occurs. Delayed hypersensitivity responses are reduced and 
may be caused by Langerhan cell depletion or damage in the irradiated 
skin. 57 
4. Ophthalmological  effects- 
Evidence of psoralen induced cataract is mainly based on 
experimental studies. However bilateral punctate cortical opacities have 
been reported.  
Because some uncertainty remains about the risk of eye toxicity, it 
is recommended that appropriate UVA opaque spectacles be worn during 
 the entire period of increased photosensitivity after psoralen ingestion. 
Obviously there is no risk with topical or bath PUVA. 58 
DRUG INTERACTIONS 
  Photosensitizing medications such as tetracyclines, phenothiazines, 
sulfa drugs and thiazide drugs may lead to additive phototoxicity and 
therefore preferably avoided. 
Reduced levels of 8-MOP may occur with concomitant phenytoin 
treatment. This is due to the induction of hepatic enzymes. Similar 
modifications may also occur with barbiturates and alcohol. 
 
OTHER FORMS OF PUVA THERAPY 
TOPICAL PUVA 
Application of psoralens in creams, ointments or lotions followed 
by UVA radiation is effective in clearing psoriasis. Two psoralens are 
currently used topically 
1. TMP(4,5’,8 Trimethyl psoralen, Trioxsalen) 
2. 8-MOP(Methoxypsoralen, Methoxalen) 
TMP is more potent topically. The photosensitivity action spectrum 
is within the range of 330-340nm.After application of 8-MOP or TMP as 
an ointment ,cream or alcoholic solution, there is gradual increase in 
photosensitivity in the first hour that remains high for several hours. 
 Technique: 
 8-MOP or TMP in a suitable vehicle is applied to the skin area to 
be treated. Irradiate it when photosensitivity is maximal, 1 hour after 
application. Immediate irradiation may be tried.59 The skin is cleansed 
with soap and water immediately after irradiation to decrease 
photosensitivity.  The main disadvantages are: 
a. Application is laborious and time consuming. 
b. Nonuniform distribution on the skin surface induces 
unpredictable phototoxic erythema and irregular patches of 
pigmentation. 60 
c. Allergic contact and photocontact dermatitis.61 Use of topical 
PUVA is now limited to psoriasis of palms and soles. 
BATH PUVA 
It consists of 15 to 20 minutes of whole body immersion in a 
solution of 8-MOP. Irradiation needs to be performed immediately as 
photosensitivity decreases rapidly. Dose-0.5to 0.8mg is used per liter of 
water. 
Advantages: 
1. Uniform drug distribution over skin surface 
2. Very low plasma psoralen levels and hence gastrointestinal and eye 
toxicity can be avoided. 
3. Lower cumulative UVA dose and therefore less carcinogenic risk. 
 For bathing suit delivery the patient is enclosed in a polythene bag 
with 4litres liquid for 15mins, concentration of 0.5 and 3.75mg may be 
used. Advantages of bath suit delivery are: 
1. It requires only less amount of water and psoralen solution. 
2. It can be carried out at home with sunlight as the UVA source 
(PUVA SOL). 
3. The cost of the drug is less compared to water delivery and UVA 
source. 
4. Systemic side effects like nausea and cataracts do not occur. 
5. Easy and less time consuming. 
Disadvantages: 
1. The entire body surface especially the head does not common in 
contact with the drug. 
2. The concentration of the drug may not be uniform in bath suit. 
  HAND and FOOT PUVA units are also available-This can be used 
for treatment of localized disease. 
Mouth PUVA: 62 
This new variant of PUVA therapy was tried for oral lichenoid 
lesions using topical application of Trioxsalen ointment. 
PUVA – Turban: 63 
 This is another method to treat Alopecia areata. In this method, a 
cotton towel is soaked in diluted bath water solution containing 8-MOP 
 (0.0001%, 1 mg/ml) at 37o C. It is wrung gently to remove excess water 
and wrapped around patient’s head in a turban fashion for 20 minutes. 
This is directly followed by UVA radiation. 
Several modes of delivery of psoralens are under research. It was 
found that sublingual delivery of psoralen in skin type 1 and 2 may be 
useful.64 It reduces the risk of hepatic and renal damage in patients who 
already have dysfunction of these two organs. Side effects like nausea 
and intolerance are also reduced. 
 
PUVA FOR PSORIASIS:     
PROTOCOLS: 
Many protocols have been used and although they are slightly 
different, they share the same basic principles of using regularly repeated 
PUVA exposures. Generally PUVA protocols have 2 phases 
1. Clearance phase-Aimed at psoriasis suppression 
2. Maintenance phase characterized by a tapering to a minimal 
number of regular visits in an effort to maintain and extend 
remission. 
       There are 2 classic protocols- The American and European 
schedules. 65,66 
 
 
 DIFFERENCE BETWEEN US AND EUROPEAN PROTOCOLS: 
 UNITED STATES EUROPE 
UVA dosimetry 
Predetermined dose 
according to skin 
phototype 
Individualized dose 
according to MPD 
determination 
Frequency of treatments 2-3 times/week 4 times/week 
Dose increments Predetermined Individualized 
Principle of approach Rigid and cautious Flexible and aggressive 
Goal 
To clear without 
ponderance testing 
and acute side effects 
To clear rapidly before 
maximum pigmentation 
develops 
 
 
Skin photo type dependant dosimetry in American protocol67 
Skin type Initial dose (J/cm2) Increments (J/cm2) 
1 1.0 0.5 
2 2.0 0.5 
3 3.0 0.5 
4 4.0 1.0 
5 5.0 1.0 
6 6.0 1.0 
 
 
 
 The study results of a Us Cooperative Clinical Trial (USCCT) and 
European Protocol Study (EPS) for treatment of psoriasis68,69 
 
USA EUROPE 
No of patients 1139 3175 
Results better than marked improvement 1005(85%) 2785(89%) 
Exposures required for clearing (median) 25 20 
Duration of treatment (weeks) 12.7 5.3 
Cumulative dose   (J/cm2) 245 96 
 
  Indian skin comes under 4 and 5 phototype and is usual to start 
with 4.5 J/cm2 and increments of 0.5 J/cm2 based on skin response. 
Maximum UVA dose that can be reached is 
 
 
Maintenance schedule: 
The final clearance dose of radiation is held constant and frequency 
of treatments gradually reduced. If a significant (>5%) amount psoriasis 
begins to return, the frequency of treatment can be increased or the 
clearance schedule restarted. 
1 and 2 8-12 J/cm2 
3 and 4 12-16 J/cm2 
5 and 6 16-20 J/cm2 
 Combination treatment: 
Topical combination-PUVA has been combined with other 
treatment form to improve efficacy and to reduce possible side effects. 
Topical adjuvant therapies include glucocorticoids, anthralins, tar and 
recently calcipotriol and tazarotene.  
Methotrexate: 
The combination of PUVA and Methotrexate can reduce the 
duration of treatment, number of exposures and is also effective in 
clearing psoriasis unresponsive to PUVA or UVB alone. Methotrexate is 
begun three weeks before PUVA therapy in a dosage of 2.5 to 5 mg at 
12h intervals for three days each week. This is continued throughout the 
clearance phase of PUVA therapy.70 Methotrexate is also delivered at a 
total dose well below the minimum dose reported for hepatotoxicity. This 
combination if used for a long time could be hazardous because PUVA 
and Methotrexate may act synergistically in the development of skin 
cancers. 
RETINOIDS: RE-PUVA 
The therapeutic efficacy of PUVA is dramatically increased when 
combined with Retinoids. Etretinate and Acitretin are administered daily 
2 weeks prior to initiation of PUVA and this combination is continued 
throughout the clearing phase. RE-PUVA reduces the number of 
exposures and the total cumulative UVA dose and also clears the disease 
 in those patients who could not be brought into remission with PUVA 
alone. As an additional benefit, retinoids may protect against long term 
carcinogenic effects of PUVA mainly by reducing the number of 
exposure and also by their cancer protective effect. 
 
PUVA FOR VITILIGO 
Psoralen photochemotherapy is one of the effective therapies in 
vitiligo. The exact mechanism of repigmentation of individual skin in 
vitiligo cannot be clearly defined. 
The following hypothesis has been proposed in vitiligo. 71 
1. Reactivation of inactive melanocytes in the vitiliginous patches. 
2. Release of an inhibited tyrosinase enzyme 
3. Induction of migration of active melanocytes from surrounding 
normal epidermis and hair follicles. 
4. Increased tolerance to UV exposures and thereby stronger 
stimulation of the melanocytes  
5. Correction of the structural abnormalities in the melanocytes in 
vitiligo skin. 
           The chemical observation of perifollicular repigmentation in 
vitiligo is an early change after PUVA therapy. There is activation of 
melanocytes located in outer root sheath of hair follicle which divide, 
 proliferate and migrate upward to achromic areas, visible as follicular 
pigmentation clinically. 72 
            PUVA may deplete VAMA (Vitiligo associated antigen) and 
impair the function of Langerhan cell, thus blocking the immune induced 
damage. Recently it was found out that leucotriene C4 and TNF-α 
released by keratinocytes secondary to UV damage causes melanocyte 
migration in vitro. 73 
              Oral 8-MOP and TMP are the photosensitisers used frequently. 
To induce repigmentation, patients need constant long term therapy (12-
24 months). Because oral TMP is much less phototoxic than 8-MOP, it is 
preferred for treatment with sunlight as radiation source. Responsiveness 
is defined as the development of perifollicular macules of repigmentation. 
              Topical 8-MOP is used in the concentration of 0.05% to 0.1% in 
Vitiligo in patients with less than 20% body surface involvement. 
              The treatment is started at low dose of 4j/cm2 of UVA and 
subsequent increments made until a uniform erythema occurs over the 
lesions or a total dose of 8j/cm2 is reached and treatments are given twice 
a week. 
               The perifollicular repigmentation is usually seen after 5weeks of 
alternate day therapy (approximately 15 treatments).Face and neck areas 
respond much better than lips, finger tips and bony prominences. 
                    Various international studies have shown the effect of PUVA 
in vitiligo. A ten year study was done in St. Johns Institute of 
Dermatology, UK showing the efficacy of PUVA in widespread 
vitiligo.74 
 
PUVA for  PARAPSORIASIS  and  CUTANEOUS  T  CELL  LYMPHOMAS: 
             PUVA is also effective in the treatment of Parapsoriasis. A large 
clinical trial done in Germany shows the effect of PUVA in various types 
of parapsoriasis. 75 
             PUVA is dramatically effective in early stages of Cutaneous T-
Cell Lymphomas (1A and 1B) when it induces complete and long lasting 
remissions. 76 The mode of action is direct phototoxic destruction of the 
atypical cells in epidermis and dermis. 
                Treatment schedule and dosimetry in photochemotherapy 
include clearing phase, a maintenance phase and follow up phase without 
therapy. The initial treatments consists of two exposures per week for 1 
month and one exposure per week for 2 months  .The patient is monitored 
regularly after stopping treatment. 
              In later stages PUVA may reduce the tumor cell burden and thus 
act synergistically with other treatment. 77 
 
               
 PUVA FOR LICHEN PLANUS: 
               PUVA is an effective alternative for systemic steroids in 
generalized Lichen planus. A bilateral comparative study done in the US 
shows the efficacy of PUVA in generalized Lichen planus.78 However 
Lichen planus may become resistant to treatment with PUVA than 
psoriasis. 
               Bath PUVA can also clear Lichen planus and combined PUVA-
Etretinate may accelerate clearing. 79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
AIM OF THIS STUDY 
 
BACKGROUND: 
Photochemotherapy is an efficient method of treating various 
dermatological disorders. With appropriate administration and regular 
monitoring it can be used safely in the treatment of various common 
dermatoses. 
 
OBJECTIVES: 
1. To evaluate the efficacy of PUVA therapy in the treatment of 
a. Psoriasis vulgaris involving >20% of Body surface area, 
b. Vitiligo vulgaris involving >20% of Body surface area, 
c. Generalized lichen planus and 
d. Parapsoriasis. 
2. To asses the side effects of PUVA during treatment. 
3. To observe the patient compliance for PUVA therapy. 
 
 
 
 MATERIALS  AND METHODS 
55 patients who attended the out patient clinic at the Department of 
Dermatology, Government General Hospital, Chennai were included in 
the study. 
Selection criteria: 
1. 20 patients with psoriasis vulgaris involving greater than 20% of 
the body surface area. 
2. 20 patients with stable vitiligo vulgaris involving greater than 20% 
of the body surface area. 
3. 10 patients with generalized lichen planus  
4. 5 patients with large plaque parapsoriasis. 
The diagnosis of Psoriasis, Vitiligo and Lichen planus was made 
on clinical grounds. 
The diagnosis of Parapsoriasis made based on skin biopsy and 
Histopathological examination. 
Exclusion criteria: 
1. Age less than 18 years 
2. Pregnant and lactating women 
3. Photosensitive disorders 
4. Significant hepatic, renal, cardiac dysfunction 
5. Family history or previous history of malignant melanoma 
 6. H/O inorganic arsenic intake or ionizing radiation 
7. H/O skin carcinoma or photo damage 
8. Chronic alcoholics 
9. Active infection like tuberculosis 
10. Cataract 
11. Systemic therapy within 8 weeks. 
All patients were explained about the disease and the benefits and 
side effects of the drugs were discussed with them. Consent was obtained 
from all patients before initiation of therapy.  
All patients were evaluated as follows: 
1. History-The onset and duration of the disease, h/o any drug intake, 
 
      h/o any photosensitive diseases, etc were  taken 
 
2. General examination 
 
3. Systemic examination 
 
4. Dermatological examination 
 
5. Ophthalmological evaluation 
 
6. Investigations: 
 
a. Complete hemogram 
 
b. Urine analysis 
 
c. Blood sugar, urea, creatinine 
 
d. Liver function tests 
 
 TREATMENT PROTOCOL AND METHODOLOGY 
 
The study population included  
Group 1: 20 patients with Psoriasis vulgaris.  
Oral 8-methoxypsoralen crystalline tablets (10mg) at a dose of 
0.6mg/kg rounded up to the nearest 10mg was advised to be taken in 
empty stomach. After 2 hours, they were exposed to UVA radiation in the 
UVA cabinet. The starting UVA dose was determined by skin type 
according to the U.S treatment protocol. Treatment was given twice 
weekly on Mondays and Thursdays. Patients were advised to wear UV 
blocking sunglasses during exposure in the cabinet and also for 24hours 
after treatment. Men wore genital protection in the cabinet. UV irradiance 
of the cabinet was measured using UVA radiometer.  
Exposure time was calculated in seconds using the formula: 
 
                             Time (in sec) =    Required dose (J/cm2) ×1000 
                                                               Irradiance (MW/cm2) 
 
 
          In our study all patients belonged to the skin phototype IV and V 
and hence treatment was started with 4 J/cm2. Subsequent increments of 
0.5J/cm2 were given based on response to therapy and presence or 
absence of erythema. 
 
 FOLLOW UP: 
 
                 Patients were followed up every week until cessation of 
treatment. Complete haemogram, LFT, Blood urea, Serum creatinine was 
done every 2 months. Adverse effects reported by the patient or noticed 
were recorded. Only the emollient liquid paraffin was allowed to be 
applied topically. 
Efficacy of treatment: 
                Severity and extent of psoriasis was evaluated using the 
Psoriasis Area Severity Index (PASI). Severity of erythema (E), 
Desquamation (D) and Induration (I) was recorded on a 5 point scale as 
follows: 
 0 = Nil 
 1 = Mild 
 2 = Moderate 
 3 = Severe 
 4 = Very severe 
 
The area of involvement was recorded on a 7 point scale as follows: 
 0 = Nil 
 1 = <10% 
 2 = 10-30% 
 3 = 31-50% 
  4 = 51-70% 
 5 = 71-90% 
 6 = 91-100% 
PASI was calculated as follows: 
PASI = 0.1(EH+IH+DH)AH + 0.2(EU+IU+DU)AU +0.3(ET+IT+DT)AT +0.4(EL+IL+DL)AL 
A - Area 
H - head  
U - upper limb  
T - trunk 
L - lower limb 
 
Group 2- 20 patients of vitiligo vulgaris: 
                      PUVA was started and administered in the same manner as 
mentioned above and was given twice weekly on Wednesdays and 
Saturdays. The total dose of PUVA in each sitting did not exceed 8J/cm2. 
The period of study was taken as 6 months and the degree of 
pigmentation was assessed every month based on Vitiligo Area Severity 
Index (VASI) score.  
                       The percentage of vitiligo involvement is calculated in 
terms of hand units. One hand unit, which encompasses the palm plus the 
volar surface of all digits, is approximately equivalent to 1% of total 
 BSA. The degree of pigmentation is estimated to the nearest of one of the 
following percentages:  
100% - complete depigmentation, no pigment present.  
90%   - specks of pigment present. 
75%   - depigmented area exceed the pigmented area.  
50%   - pigmented and depigmented areas equal. 
25%   - pigmented area exceeds depigmented area.  
10%   - only specks of  depigmentation present.  
             The VASI for each body region is determined by the product of 
the area of vitiligo in hand units and extent of depigmentation within each 
hand unit measured patch.  
       Total body VASI = All body sites (Hand units) × (residual   depigmentation).  
 
               Group 3 - 10 patients with generalized lichen planus were 
included for PUVA therapy. The PUVA was started as mentioned above 
and given for a period of approximately 3 months. The activity of the 
disease was noted by selecting a particular area like one hand or one leg 
and the number of papules in that area was counted approximately. The 
number of papules was counted again in the same area every month. 
Symptomatic improvement as told by the patient as well as the side 
effects was noted.  
 
                Group 4 - 5 patients of parapsoriasis. PUVA was started as 
mentioned above and continued for an average of 3 months. The 
percentage of involvement calculated initially by hand unit method which 
is equal to 1% and the improvement calculated every month. The side 
effects were also noted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
OBSERVATION AND RESULTS 
 
 
 
AGE DISTRIBUTION-  
The mean age in various study groups were as follows: 
 
 
SEX DISTRIBUTION-  
 
GROUP MALES FEMALES 
1 15 5 
2 12 8 
3 6 4 
4 4 1 
 
 
 
GROUP Mean Age (years) Range (years) 
1 36.1 23 – 60 
2 39.4 20 - 54 
3 40.6 30 - 56 
4 36.6 32 – 40 
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SEX DISTRIBUTION
Females
 33%
Males
67%
 
 DURATION OF ILLNESS-   
Group Mean Duration of illness 
1 2.15 yrs 
2 5.2 yrs 
3 1.15 yrs 
4 5.4 months 
 
FAMILY HISTORY- 
Family history was elicited in group 1 and 2. 
Group % of family history 
1 10 
2 0 
 
Group 1: REDUCTION IN PASI SCORE : 
             The mean PASI scores at 0, 4, 8, 12 and 16 weeks have been 
tabulated and the reduction depicted in Figure below. 
             The graph in the figure shows the gradual reduction in PASI, 
with a mean PASI score of 29.78 at 4 weeks, 16.88 at 8 weeks, 8.12 at 12 
weeks, 1.01 at the end of 16 weeks. These values correspond to a 
percentage reduction of 43%, 72%, 89% and 96% at the end of 4, 8, 12, 
and 16 weeks respectively as depicted in Figure below. 
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MEAN CUMULATIVE  UVA DOSE AND NUMBER OF UV 
EXPOSURES AND TOTAL DURATION OF TREATMENT  
 Group 1 
Average no. of UVA exposures 
 32 (26-40 ) 
Duration of treatment(weeks) 
 16.14 (13-20) 
Mean cumulative UVA dose 
 244 (216-265) 
 
RESPONSE TO THERAPY 
Based on the percentage reduction in PASI results were graded as 
excellent, good and moderate. 
Results No. of patients Percentage
% reduction in PASI score 
at 16 weeks 
Excellent 
 14 70% >95% 
Good 
 4 20% 80-95% 
Moderate 
 0 0% 50-80% 
In this group one patient had exacerbation of lesions and one 
patient discontinued therapy. 
STATISTICAL ANALYSIS: 
 While performing a Regression Analysis with the input factors 
being the initial PASI score (PASI 0) and cumulative UVA dosage across 
16 weeks we are able to arrive at the regression equation for the final 
 PASI score at the end of 16th week (PASI 16). The P value obtained from 
the test is 0.015. 
 Any P value <0.05 is considered statistically significant. Hence our 
P value of 0.015 implies that there is a significant reduction in PASI score 
after PUVA therapy. 
 
Group 2 : REDUCTION IN VASI SCORE: 
The mean VASI score at 0, 2, 4, 6 months has been tabulated and 
its reduction depicted in Figure below 
VASI Reduction (Group 2)
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PERCENTAGE REDUCTION IN VASI:  
 The percentage reduction in VASI score were 12.5%, 23.4%, 
35.82% in 2, 4 and 6 months respectively as depicted in figure below:  
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MEAN CUMULATIVE DOSE AND NO.OF UV EXPOSURES: 
 
 Group 2 
Average no of UV exposures 60 
Duration of treatment(months) 6 months 
Mean cumulative  UVA dose 273.05 J 
 
 
  
RESPONSE TO THERAPY-Assessment of improvement in 6 months 
 
Results No. of  patients Percentage 
% of 
improvement in 
VASI score 
Poor response 2 10% 1-25% 
Moderate response 17 85% 25-50% 
Good response 0 0 51-75% 
Excellent response 0 0 >76% 
 
 
One patient discontinued treatment on her own. 
 
 
 
STATISTICAL ANALYSIS: 
 While performing a Regression Analysis with the input factors 
being the initial VASI score (VASI 0) and cumulative UVA dosage 
across 6 months we are able to arrive at the regression equation for the 
final VASI score at the end of 6th month (VASI 6). The P value obtained 
from the test is 0.012. 
 Any P value <0.05 is considered statistically significant. Hence our 
P value of 0.012 implies that there is a significant reduction in VASI 
score after PUVA therapy. 
 
 
  
 
Group  3 – Lichen planus: 
 The improvement of lichen planus lesions was assessed based on 
decrease in the number of papules in a targeted area .The mean number of 
papules at 0, 4, 8 and 12 weeks is depicted in the figure below. 
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Group 4 
The assessment of improvement of parapsoriatic lesions were made 
on the reduction in body surface area involved. The mean BSA at 0, 4, 8 
and 12 weeks is shown in figure below.  
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Two patients responded poorly to the therapy. 
 
 
 
 
 
 
 
 ADVERSE EFFECTS: 
The common adverse effects seen in all patients undergoing PUVA 
has been tabulated: 
Side effects Group 1 Group 2 Group 3 Group 4 
Nausea 3 1 0 1 
Pruritus 2 2 2 0 
Erythema 2 3 1 0 
 
A total of 5 patients had nausea after taking psoralen tablet. 6 
patients had pruritus which was exaggerated during the first few weeks of 
therapy. 6 patients also had erythema after treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DISCUSSION 
Group 1 
The efficacy of PUVA in the treatment of psoriasis has been 
documented and confirmed by various clinical trials in many parts of the 
world.  
In our study the number of patients who had excellent response 
were 14 (70%) and a good response were 4 (20%).  50% reduction in 
PASI was seen by 8 weeks and the mean duration of treatment was 16.4 
weeks and a the mean cumulative dose of 244 Joules. Hence our study 
results show that PUVA is a good therapeutic option for the treatment of 
psoriasis. 
In the U.S. Cooperative Clinical Trial (USCCT), percentage of 
patients with marked improvement of complete clearing were 88% 
whereas in our study it was 70%. Cumulative UVA dose in the USCCT 
was 245 Joules.68 
Though our study was of a low number, the results were consistent 
with those of the U.S. multicenter trial and other international studies 
Group 2 
In our study about 17 patients (85%) showed a moderate response 
within 6 months of treatment. The response was noted only after 6-8 
weeks after therapy initially. 
  However we also noted that sites like the trunk, arms and legs 
responded well whereas the acral regions, periorificial regions and bony 
prominences did not respond well to treatment. The response is better if 
PUVA is continued for 9-12 months as various studies indicate. To avoid 
the long term complications our patients were given PUVA for only 6 
months and the efficacy noted. The patients were then advised to continue 
on PUVASOL and this improved pigmentation. The perifollicular type of 
repigmentation was the commonest type noted.  
Our study is comparable with that done in St. John’s Institute of 
Dermatology, London, which shows that PUVA is moderately effective 
in widespread vitiligo.74 Though our study showed only moderate effect 
in Vitiligo vulgaris, it still continues to be a good option as the patients 
had been affected for a long duration. 
 
Group 3 
The improvement noted in generalized lichen planus was also 
satisfactory. 80% of the patients showed good symptomatic response 
within 2-4 weeks of therapy. There was flattening of the papular lesions 
and disease activity was controlled well. However patients had 
postinflammatory hyperpigmentation. 
 Our study is comparable to the study done by Gonzalea E, et al.78 
 
 Group 4 
Parapsoriasis is considered to be one of the indications of PUVA 
therapy. As mentioned in the study done by Westphal H, Walter A,          
et al.,75 three patients in our study showed 90% clearance of lesions 
within 3 months of therapy. However two patients did not respond 
satisfactorily. But still PUVA should be considered a therapeutic option 
for parapsoriasis. 
The adverse effects noted in our study were all minor, none of 
which required cessation of treatment. Nausea was a side effect seen in 
about 6 patients which improved once the patients were advised to take 
the drug after having a light meal. A few patients had increased pruritus 
during the initial few weeks of treatment which improved after sometime 
and supportive measures like antihistamines.  
Erythema was another side effect noted. But it was mild in most of 
the cases which improved with topical calamine application. 
 However the patient compliance was not satisfactory as patients 
had to come twice weekly to the hospital for treatment. Short therapy had 
better compliance than long term therapy like vitiligo therapy. A good 
motivation and counseling were useful to improve compliance. 
 
 
 
  
CONCLUSION 
 
1. PUVA is an effective and safe therapy for the treatment of 
Psoriasis vulgaris as evidenced by the response rate of 90% seen in 
our study with only minimal side effects like erythema, nausea and 
pruritus.         
2. PUVA also induces a moderate amount of repigmentation in 
Vitiligo vulgaris during 6 months of therapy. Hence careful patient 
counselling is needed before starting PUVA, as it takes a long 
duration to induce extensive repigmentation. 
3. PUVA also results in satisfactory improvement in generalized 
Lichen planus and helps in the clearance of Parapsoriasis. 
4. Thus PUVA can be considered a valuable mode of therapy for the 
above conditions like Psoriasis vulgaris, generalized Lichen planus 
and Parapsoriasis. It is also useful in Vitiligo when patient does not 
respond to other modalities of treatment. 
 
 
 
 
  
Group 1: PSORIASIS VULGARIS – Before and After 16 weeks of treatment. 
 
 
 
    
 
 
 
  
Group 1: PSORIASIS VULGARIS – Before and After 16 weeks of treatment. 
 
 
 
    
  
Group 1: PSORIASIS VULGARIS – Before and After 16 weeks of treatment.   
                     
 
    
   
 
 
  
Group 2: VITILIGO VULGARIS – Before and after 6 months treatment  
 
    
 
    
 
 
  
Group 2: VITILIGO VULGARIS – Before and after 6 months treatment 
     
 
  
    
 
  
Group 2: VITILIGO VULGARIS – Before and after 6 months treatment 
       
 
 
      
 
 
  
Group 3: LICHEN PLANUS – Before and After 12 weeks of treatment. 
 
 
 
                            
  
 
 
  
Group 3: LICHEN PLANUS – Before and After 12 weeks of treatment. 
 
 
 
                               
 
  
Group 4: PARAPSORIASIS – Before and After 3 months of treatment. 
 
 
 
 
 
 
 
 
 
  
 
Group 4: PARAPSORIASIS – Before and After 3 months of treatment. 
 
 
 
 
  
 
 
 
 
 
 
Erythema after PUVA therapy 
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 PROFORMA 
Name:      Date: 
Age/Sex:      OP No: 
Occupation: 
Address:      Case No: 
 
HISTORY 
Duration:   years   months 
Itching:    □ Yes   □ No 
H/o Previous Treatment:   Topical  Systemic 
 
EXACERBATION WITH: 
□ Cold climate  □ Sunlight  □ Dialysis 
□ Infection   □ Trauma  □ Emotional Factors 
□ Puberty   □ Pregnancy □ Menopause 
Past History: 
□ Hypertension  □ Diabetes  □ TB □ IHD  
□ Thyroid disorders □ Asthma  □ Photosensitivity 
 □ Cutaneous malignancy   □ Radiotherapy 
 □ Pregnant   □ Lactating mother 
Drugs taken for any other condition: 
Family History:  □ Mother  □ Father 
    □ Sibling  □ Others 
 Personal History:  □Alcohol  □Smoking 
Menstrual History:   
GENERAL EXAMINATION: 
  □ Pallor  □ Icterus  □ Edema   
  Pulse:   BP: 
  Weight: 
SYSTEMIC EXAMINATION: 
   CVS: 
   RS   : 
   P/A  : 
   CNS : 
   Musculoskeletal: 
   ENT : 
   Dental: 
 
DERMATOLOGICAL EXAMINATION 
 Skin lesions:  Site 
    Morphology 
    Surface area involved 
    Signs 
 Mucous membrane 
 Palms and soles 
  Scalp 
 Hair 
 Nail 
DIAGNOSIS: 
INVESTIGATIONS:     
 Blood Sugar:  Urea:   Creatinine: 
 Blood VDRL  HIV:   Skin biopsy: 
 Ophthalmological examination: 
Date      
Hb      
TC      
DC      
ESR      
Platelets      
SGOT      
SGPT      
SAP      
Total Protein      
Total Bilirubin      
 
 
 
 
 
  
PUVA CHART: 
Date Cycle Dose Duration Cumulative Dose Side Effects
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
 
  
 
FOLLOW UP:   
 
 In Psoriasis Vulgaris: 
Week PASI Score Cumulative dose 
0   
4   
8   
12   
16   
 
In Vitiligo vulgaris: 
Months VASI Score Cumulative dose 
0   
2   
4   
6   
 
In Lichen planus:        Area chosen: 
Week No. of papules Cumulative dose 
0   
4   
8   
12   
 
In Parapsoriasis: 
Week BSA% Cumulative dose 
0   
4   
8   
12   
 
 
 
